InspireMD Q3 revenue beats analyst estimates
NSPR•InspireMD's third-quarter revenue rose year over year to $2.24 million, beating the $2 million analyst estimate. Its net loss of $9.76 million and operating loss of $9.95 million were also narrower than estimates.
1. Quarterly results
InspireMD reported third-quarter revenue of $2.24 million, compared with the $2 million analyst consensus. The company posted a net loss of $9.76 million, or $0.12 per basic share, and an operating loss of $9.95 million; analysts had estimated losses of $13.54 million and $13.57 million, respectively.
2. Product and outlook
The company received FDA approval for CGuard Prime for transcarotid artery revascularization (TCAR) and expects to begin U.S. sales in the fourth quarter of 2026. InspireMD is targeting a potential relaunch of CGuard Prime for carotid artery stenting (CAS) in the first half of 2027.
3. Revenue and costs
InspireMD said a voluntary recall of the CGuard Prime CAS delivery system reduced U.S. revenue and affected gross profit. International revenue grew, but a shift toward countries with lower average prices pressured gross margin. Operating expenses fell due to workforce reductions and related restructuring costs.
